Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

May 1, 2027

Conditions
Gastric Intestinal Metaplasia
Interventions
DRUG

Berberine hydrochloride

Subjects will be instructed to take three tablets (300mg) of Berberine hydrochloride two times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.

DRUG

Placebo

Subjects will be instructed to take three tablets (300mg) of placebo two times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.

All Listed Sponsors
lead

Xijing Hospital of Digestive Diseases

OTHER